Skip to content
10-K

Annual Report

SYNAGEVA BIOPHARMA CORP

0001193125-15-065709

← back to feed
Filed
Feb 26, 2015 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2014 · Feb 20, 2015 36.96M sh
Shares Diluted FY 2014 · Dec 31, 2014 32.72M sh
Capex FY 2014 · Dec 31, 2014 $16.77M
Short Term Investments FY 2014 · Dec 31, 2014 $364.26M
Cash And Equivalents FY 2014 · Dec 31, 2014 $82.65M
Stockholders Equity FY 2014 · Dec 31, 2014 $473.24M
Current Liabilities FY 2014 · Dec 31, 2014 $25.24M
Total Liabilities FY 2014 · Dec 31, 2014 $30.96M
Current Assets FY 2014 · Dec 31, 2014 $457.83M
Total Assets FY 2014 · Dec 31, 2014 $504.2M
Eps Diluted FY 2014 · Dec 31, 2014 −$5.89
Eps Basic FY 2014 · Dec 31, 2014 −$5.89
Sga Expense FY 2014 · Dec 31, 2014 $54.5M
Rd Expense FY 2014 · Dec 31, 2014 $142.64M
Net Income FY 2014 · Dec 31, 2014 −$57.67M
Net Income FY 2014 · Dec 31, 2014 −$192.65M
Net Income FY 2014 · Sep 30, 2014 −$48.32M
Net Income FY 2014 · Jun 30, 2014 −$50.24M
Net Income FY 2014 · Mar 31, 2014 −$36.42M
Operating Income FY 2014 · Dec 31, 2014 −$57.31M
Operating Income FY 2014 · Dec 31, 2014 −$192.13M
Operating Income FY 2014 · Sep 30, 2014 −$48.04M
Operating Income FY 2014 · Jun 30, 2014 −$50.31M
Operating Income FY 2014 · Mar 31, 2014 −$36.48M
Revenue FY 2014 · Dec 31, 2014 $1.24M
Revenue FY 2014 · Dec 31, 2014 $6.49M
Revenue FY 2014 · Sep 30, 2014 $1.33M
Revenue FY 2014 · Jun 30, 2014 $2.34M
Revenue FY 2014 · Mar 31, 2014 $1.59M